Drug Development

Bial accused of negligence in lethal drug trial — Nature

David Webb, president of the British Pharmacological Society, says that new revelations at a recent conference proved that the investigators from Portuguese biotech Bial were “flying blind” when they started a trial which left one patient dead and four others with lingering neurological damage.

The revelation, reports Nature, is that Bial overlooked the pharmacodynamic data on a low dose of BIA 10-2474 before taking the dose higher.

“Without the PD data, they were flying blind. That’s when accidents happen,” says Webb. “I think that was negligent.”

Bial, though, denies the allegation:

“All official reports about the trial were inconclusive and all have considered this event as unpredictable, and that there was no indication whatsoever, including in the pre-trials, that could have predicted this outcome.”

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 37,500+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Biotech Investment Analyst
SV Health Investors Boston, MA
Director, Program Management
Contrafect Corporation New York, NY
Director, Translational Sciences
Cadent Therapeutics Cambridge, MA

Visit Endpoints Careers ->